The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The starting point was an IRAK4 kinase inhibitor identified from historical kinome selectivity data. A homology-model based on MST1 was used for [...]
< 1 minute read
Nov. 3, 2021
An Oral BMS HPK1 Inhibitor Tool Compound from Homology Modeling
BMS compound 24 - HPK1
50x family-selective HPK1 kinase inhibitor tumor clearance w/ PD-1i (oral 100 mpk BID) from IRAK4 inhibitor and homology modeling ACS. Med. Chem. Lett., Feb. 19, 2021 Bristol Myers Squibb, Cambridge, MA
Loading...
